⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

PV is a chronic, manageable blood cancer — not a death sentence. Most people with PV live for decades with proper treatment. Median survival with modern management exceeds 15–20 years, and many patients have a near-normal life expectancy.
The JAK2 V617F mutation is found in over 95% of PV patients. This single genetic test is the cornerstone of diagnosis. A small percentage carry a JAK2 exon 12 mutation instead. If both are negative, PV is extremely unlikely.
Your hematocrit must stay below 45%. The CYTO-PV trial proved that keeping hematocrit below 45% (through phlebotomy and/or medication) dramatically reduces the risk of blood clots and cardiovascular death. This is the single most important treatment target.
Low-dose aspirin is standard for nearly all PV patients. The ECLAP trial showed that aspirin (81–100 mg daily) reduces thrombotic events without excessive bleeding in most patients.
Phlebotomy is the foundation of treatment. Therapeutic blood draws remove excess red blood cells and are the first-line treatment for all PV patients. Many low-risk patients are managed with phlebotomy plus aspirin alone.
Ropeginterferon alfa-2b (Besremi) is the first interferon approved specifically for PV. FDA-approved in 2021, it can reduce the JAK2 V617F allele burden over time and may modify the disease course. It is increasingly used as first-line cytoreduction.
Ruxolitinib (Jakafi) is effective when hydroxyurea fails. For patients who are resistant to or intolerant of hydroxyurea, ruxolitinib controls blood counts, reduces spleen size, and improves symptoms.
The biggest risks are blood clots and disease transformation. Thrombosis (blood clots in arteries or veins) is the leading cause of illness and death in PV. Over many years, a small percentage of patients progress to myelofibrosis or acute leukemia.

▼ Collapse

Understanding Polycythemia Vera

Polycythemia vera (PV) is a chronic blood cancer classified as a myeloproliferative neoplasm (MPN). In PV, the bone marrow produces too many red blood cells, and often too many white blood cells and platelets as well. The excess red blood cells thicken the blood, increasing the risk of blood clots (thrombosis), which can cause strokes, heart attacks, deep vein thrombosis, and pulmonary embolism.

PV is caused by an acquired (not inherited) mutation in the JAK2 gene, found in a blood-forming stem cell. This mutation causes the JAK-STAT signaling pathway to be permanently turned on, driving uncontrolled blood cell production. The JAK2 V617F mutation is present in over 95% of PV patients; approximately 2–3% carry a JAK2 exon 12 mutation instead.

PV is a chronic condition. Unlike acute leukemia, it does not require emergency treatment and typically progresses slowly over years to decades. With proper management, most patients live long and productive lives. However, PV requires lifelong monitoring and treatment to prevent complications.

Approximately 5,000 new cases per year in the United States
Approximately 180,000 people are currently living with PV in the US
Median age at diagnosis is about 60 years, but PV can occur at any age
Slightly more common in men than women
Incidence increases with age
The JAK2 V617F mutation is present in >95% of cases

PV belongs to the family of myeloproliferative neoplasms (MPNs), which also includes essential thrombocythemia (ET) and primary myelofibrosis (PMF). Key distinctions:

PV vs. Essential Thrombocythemia (ET): ET primarily raises platelets; PV primarily raises red blood cells. Both carry thrombosis risk, but PV’s risk is generally higher.
PV vs. Primary Myelofibrosis (PMF): PMF is characterized by bone marrow scarring (fibrosis) and is generally more aggressive. PV can transform into a myelofibrosis-like state over time (post-PV MF).
PV vs. Secondary Polycythemia: Secondary polycythemia (elevated red blood cells due to lung disease, sleep apnea, smoking, high altitude, or EPO-producing tumors) is NOT a cancer and is treated by addressing the underlying cause. JAK2 testing distinguishes PV from secondary causes.

The most important concept in this guide: PV management revolves around one central goal — preventing blood clots. Keeping your hematocrit below 45%, taking aspirin, and using cytoreductive therapy when needed are all aimed at this goal. Every treatment decision flows from thrombosis prevention.

Key Breakthroughs in PV

PV treatment has advanced significantly in recent years. Here are the most important developments:

FDA-APPROVED Ropeginterferon alfa-2b (Besremi) is a long-acting pegylated interferon and the first interferon therapy specifically approved by the FDA for polycythemia vera (November 2021). Unlike hydroxyurea, which only controls blood counts, ropeginterferon can reduce the JAK2 V617F allele burden over time, potentially modifying the underlying disease biology. It is given as a subcutaneous injection every two weeks (after initial titration, extended to monthly in some patients). The PROUD-PV and CONTINUATION-PV trials demonstrated non-inferiority to hydroxyurea with sustained hematologic responses and progressive molecular responses. Ropeginterferon was approved in Europe (EMA) in 2019, two years before the FDA approval.

LANDMARK TRIAL The CYTO-PV trial (Marchioli et al., New England Journal of Medicine 2013) was conducted in Italy and definitively established that maintaining hematocrit below 45% dramatically reduces cardiovascular events and deaths compared to a more lenient target of 45–50%. Patients in the strict-control group (hematocrit <45%) had a nearly four-fold lower rate of cardiovascular death and major thrombosis. This trial changed international practice and is the basis for the universal hematocrit <45% target used worldwide today.

FDA-APPROVED Ruxolitinib, a JAK1/JAK2 inhibitor, was FDA-approved for PV in 2014 based on the RESPONSE trial. It demonstrated superior hematocrit control and spleen volume reduction compared to best available therapy in patients who were resistant to or intolerant of hydroxyurea. The RESPONSE-2 trial extended these findings to patients without significant splenomegaly. Ruxolitinib provides effective symptom relief (fatigue, pruritus, night sweats) and reduces phlebotomy dependence.

UNDER FDA REVIEW Rusfertide (Takeda/Protagonist) is a hepcidin mimetic peptide for PV patients who require frequent phlebotomy. Hepcidin is the master regulator of iron absorption — by mimicking it, rusfertide restricts iron availability for red blood cell production, reducing the need for phlebotomy. The Phase 3 VERIFY trial met its primary endpoint and all four key secondary endpoints (about 77% of patients on rusfertide were clinical responders versus 33% on placebo). Based on these results, a New Drug Application was submitted in January 2026, and in March 2026 the FDA accepted it and granted Priority Review, with a decision expected in the second half of 2026. If approved it would be a first-in-class, fundamentally new mechanism for PV. (It is not yet FDA-approved; ask your hematologist whether a clinical trial or expanded access is an option.)

LANDMARK TRIAL The ECLAP trial (Landolfi et al., New England Journal of Medicine 2004) established that low-dose aspirin (100 mg daily) significantly reduces the risk of cardiovascular events in PV patients — including heart attack, stroke, pulmonary embolism, and venous thrombosis — without significantly increasing the risk of major bleeding. This trial made aspirin a standard recommendation for virtually all PV patients.

Diagnosis: The Tests You Need

PV diagnosis follows the WHO 2022 criteria and requires a combination of blood tests, genetic testing, and sometimes bone marrow biopsy.

PV is often first suspected from a routine CBC showing elevated hemoglobin and/or hematocrit. The WHO 2022 diagnostic thresholds are:

Hemoglobin >16.5 g/dL in men or >16.0 g/dL in women, OR
Hematocrit >49% in men or >48% in women, OR
Red cell mass >25% above predicted normal

Many PV patients also have elevated white blood cell counts and/or platelet counts.

JAK2 testing is the single most important diagnostic test for PV:

JAK2 V617F: Found in >95% of PV patients. A positive test in the setting of elevated hemoglobin/hematocrit is highly suggestive of PV.
JAK2 exon 12 mutations: Found in approximately 2–3% of PV patients who are V617F-negative. These patients often present with isolated erythrocytosis (elevated red cells only) without elevated platelets or white cells.
If both JAK2 tests are negative: PV is extremely unlikely. Consider secondary causes of polycythemia (lung disease, sleep apnea, EPO-secreting tumors, high altitude).

Allele burden: The JAK2 V617F variant allele frequency (VAF) — the percentage of JAK2 genes that carry the mutation — can be measured. Higher VAF is associated with more symptoms and greater risk of complications, but is not currently used to guide treatment decisions in routine practice.

Serum EPO is typically low or low-normal in PV. In secondary polycythemia, EPO is usually elevated. A subnormal EPO level supports the diagnosis of PV and is included in the WHO 2022 minor criteria. An elevated EPO level strongly argues against PV.

Bone marrow biopsy is part of the WHO 2022 major diagnostic criteria for PV. It shows characteristic findings:

Hypercellularity with trilineage proliferation (increased red cells, white cells, and megakaryocytes)
Pleomorphic, mature megakaryocytes (large platelet-producing cells with varied sizes)
No significant fibrosis at diagnosis (distinguishes PV from myelofibrosis)

Some guidelines note that a bone marrow biopsy may not be required if JAK2 V617F is positive with clearly elevated hemoglobin/hematocrit and low EPO. However, a biopsy at diagnosis provides a baseline assessment of fibrosis grade, which is useful for monitoring potential disease progression.

Has my JAK2 mutation been tested? What is my allele burden?
What is my erythropoietin (EPO) level?
Do I need a bone marrow biopsy?
Could my elevated blood counts be caused by something other than PV?
What is my risk category (low or high)?
Should I see a hematologist who specializes in MPNs?
Do I have any baseline fibrosis in my bone marrow?

Risk Stratification — Guiding Your Treatment

PV risk stratification focuses on the risk of thrombosis (blood clots), which is the primary cause of illness and death in PV. Risk determines whether you need cytoreductive therapy (medication to lower blood counts) in addition to phlebotomy and aspirin.

Risk Group	Criteria	Treatment Approach
Low Risk	Age <60 years AND no prior history of thrombosis	Phlebotomy to maintain hematocrit <45% + low-dose aspirin. Cytoreductive therapy generally not needed unless very high phlebotomy burden, uncontrolled symptoms, or progressive splenomegaly.
High Risk	Age ≥60 years OR prior history of thrombosis (blood clot)	Phlebotomy + low-dose aspirin + cytoreductive therapy (hydroxyurea or ropeginterferon as first-line options).

Beyond the traditional two-tier system, researchers are studying additional factors that may refine risk assessment:

Leukocytosis (elevated white blood cells): WBC >15,000/µL has been associated with higher thrombosis risk in some studies, though this is not yet universally incorporated into formal risk models.
JAK2 V617F allele burden: Higher VAF is associated with more symptoms, larger spleens, and higher risk of transformation to myelofibrosis, but is not currently a formal treatment trigger.
Cardiovascular risk factors: Hypertension, diabetes, and hyperlipidemia increase thrombotic risk in PV patients, just as in the general population.
Platelet count >1,000,000/µL: Extreme thrombocytosis can paradoxically increase bleeding risk due to acquired von Willebrand disease. Aspirin may need to be withheld until platelets are controlled.

Important: Risk classification is simple — only age and prior blood clot history determine your category. But “low risk” does not mean “no risk.” Even low-risk patients need hematocrit control and aspirin. The distinction matters because high-risk patients also need cytoreductive medication.

Phlebotomy — The Foundation of PV Treatment

Therapeutic phlebotomy (blood removal) is the oldest and most fundamental treatment for PV. It works by directly removing excess red blood cells, lowering hematocrit, and reducing blood viscosity.

Typically one unit (approximately 500 mL or one pint) of blood is removed per session
Sessions are performed every 1–2 weeks initially until hematocrit is below 45%
Once controlled, frequency is adjusted (every 4–12 weeks) to maintain hematocrit below 45%
Each session takes approximately 15–30 minutes
Some patients feel lightheaded or fatigued after phlebotomy; drinking fluids before and after helps
Phlebotomy intentionally causes iron deficiency over time, which actually helps by limiting the body’s ability to produce excess red blood cells. Iron supplementation should generally be avoided unless there is a specific clinical indication and your hematologist approves it.

The CYTO-PV trial established that a hematocrit target of <45% for all PV patients (both men and women) dramatically reduces cardiovascular events. Key findings:

Patients with hematocrit maintained below 45% had a nearly four-fold reduction in cardiovascular death and major thrombosis compared to those with less strict control (45–50%)
This target applies to both men and women, despite normal hematocrit ranges differing by sex
Some experts advocate for an even lower target (<42%) in patients with prior thrombosis, particularly arterial events, though this is not universally adopted

What is my current hematocrit level?
How often will I need phlebotomy?
Is my hematocrit consistently staying below 45%?
Am I needing phlebotomy too frequently? Should we discuss cytoreductive therapy?
Should I avoid iron supplements?
Can I drive home after phlebotomy, or should I arrange a ride?

Aspirin & Thrombosis Prevention

Low-dose aspirin is a cornerstone of PV treatment, recommended for virtually all patients based on the ECLAP trial.

The ECLAP trial randomized 518 PV patients to aspirin (100 mg daily) or placebo:

Aspirin reduced the combined risk of cardiovascular death, non-fatal heart attack, non-fatal stroke, and major venous thromboembolism by approximately 60%
No significant increase in major bleeding was observed
Aspirin also reduced microvascular symptoms (headache, dizziness, visual disturbances, burning/tingling in hands and feet)

Extreme thrombocytosis (>1,000,000/µL): Very high platelet counts can cause acquired von Willebrand disease, which increases bleeding risk. Check von Willebrand factor ristocetin cofactor activity before giving aspirin. Withhold aspirin until platelets are reduced if acquired vWD is confirmed.
Active bleeding or high bleeding risk: Aspirin may need to be held.
Twice-daily aspirin: Some hematologists prescribe aspirin 81 mg twice daily in patients with persistent microvascular symptoms or prior arterial thrombosis, based on pharmacokinetic data suggesting that PV patients metabolize aspirin faster than normal. This is an emerging practice, not yet universally recommended.

Thrombosis types in PV: PV patients are at risk for both arterial thrombosis (stroke, heart attack, peripheral arterial occlusion) and venous thrombosis (DVT, pulmonary embolism). Unusually, PV patients can also develop thrombosis in unusual sites such as the splanchnic veins (Budd-Chiari syndrome, portal vein thrombosis). Any unexplained blood clot in a younger person should raise the question of an underlying MPN.

Cytoreductive Therapy — When Medications Are Needed

Cytoreductive therapy (medication to reduce blood cell production) is added to phlebotomy and aspirin for high-risk patients, or for low-risk patients who need very frequent phlebotomy, have uncontrolled symptoms, or develop progressive splenomegaly.

STANDARD OF CARE Hydroxyurea (also called hydroxycarbamide) has been the most commonly used cytoreductive agent for PV for decades.

How it works: Inhibits DNA synthesis, reducing production of all blood cell lines.
Dosing: Typically started at 500–1,000 mg daily, adjusted based on blood counts. Taken orally.
Effectiveness: Controls hematocrit, white cells, and platelets effectively in most patients. Reduces thrombotic events.
Side effects: Mouth sores (oral ulcers), skin changes (darkening, leg ulcers, nail changes), nausea, mild cytopenias. Most side effects are dose-dependent and reversible.
Leukemogenic concern: There has been longstanding debate about whether hydroxyurea increases the risk of leukemic transformation. Current evidence suggests that hydroxyurea monotherapy does not significantly increase leukemia risk. The historical concern arose from studies using combination therapy (hydroxyurea + other agents), which is no longer recommended.

Not all patients respond well to hydroxyurea. The European LeukemiaNet (ELN) has defined specific criteria for resistance and intolerance:

Hydroxyurea resistance (any one of):

Need for phlebotomy to keep hematocrit <45% after 3 months of ≥2 g/day of hydroxyurea
Uncontrolled myeloproliferation (platelets >400,000/µL AND WBC >10,000/µL) after 3 months of ≥2 g/day
Failure to reduce splenomegaly by >50% or failure to completely relieve spleen-related symptoms

Hydroxyurea intolerance (any one of):

ANC <1,000/µL, OR platelets <100,000/µL, OR hemoglobin <10 g/dL at the lowest dose required to achieve a response
Leg ulcers or other unacceptable mucocutaneous toxicity
Hydroxyurea-related fever

If you meet these criteria, your hematologist should discuss switching to ruxolitinib or ropeginterferon.

Anagrelide: Specifically lowers platelet counts. Sometimes used in combination with hydroxyurea or as an alternative when platelet reduction is the primary goal. Does not control hematocrit or white blood cells. Side effects include headache, palpitations, and fluid retention.
Busulfan: An alkylating agent occasionally used in older patients who cannot tolerate other options. Carries a genuine leukemogenic risk and is reserved as a last-line option. Used only by experienced MPN specialists.

Am I low-risk or high-risk for thrombosis?
Do I need cytoreductive therapy, or can I be managed with phlebotomy and aspirin alone?
What are the pros and cons of hydroxyurea versus ropeginterferon for me?
If I am on hydroxyurea, am I meeting the ELN response criteria?
Am I developing resistance to or intolerance of hydroxyurea?
Should I consider switching to ruxolitinib or ropeginterferon?
Are there any clinical trials I should consider?
How often should my blood counts be checked?
Am I taking the right dose of aspirin?

Ruxolitinib (Jakafi)

Ruxolitinib is a JAK1/JAK2 inhibitor FDA-approved for PV patients who have had an inadequate response to or are intolerant of hydroxyurea.

FDA-APPROVED The RESPONSE trial randomized 222 PV patients resistant to or intolerant of hydroxyurea (with splenomegaly) to ruxolitinib versus best available therapy (BAT):

Primary endpoint: 21% of ruxolitinib patients achieved both hematocrit control and ≥35% spleen volume reduction, vs. 1% with BAT
Hematocrit control: 60% with ruxolitinib vs. 20% with BAT
Symptom improvement: Significant reductions in pruritus (itching), fatigue, and night sweats
5-year follow-up showed sustained responses and a trend toward fewer thrombotic events

RESPONSE-2 confirmed similar benefits in PV patients without significant splenomegaly.

Dosing: Starting dose typically 10 mg twice daily, adjusted based on blood counts and response
Infections: Increased risk of shingles (herpes zoster reactivation) — discuss vaccination or antiviral prophylaxis with your doctor
Non-melanoma skin cancers: Increased incidence observed; regular dermatologic screening recommended
Do not stop suddenly: Abrupt discontinuation can cause a rebound in symptoms, including rapid spleen enlargement and a severe inflammatory response. Always taper ruxolitinib under medical supervision.
Does not significantly reduce JAK2 allele burden: Unlike ropeginterferon, ruxolitinib primarily manages symptoms and blood counts without substantially reducing the mutant clone.

Interferon Therapy

Interferon has been used to treat PV for over 30 years, but the approval of ropeginterferon alfa-2b (Besremi) in 2019 (EMA) and 2021 (FDA) marked a major advancement.

FDA-APPROVED Ropeginterferon is a mono-pegylated, long-acting interferon alfa-2b designed specifically for PV:

Molecular response: Unlike hydroxyurea and ruxolitinib, ropeginterferon can reduce the JAK2 V617F allele burden over time. Some patients achieve complete molecular responses (undetectable JAK2 mutation). This may reduce the risk of disease transformation, though this has not been proven in randomized trials.
PROUD-PV/CONTINUATION-PV trials: Demonstrated non-inferiority to hydroxyurea in hematologic response, with superior molecular response rates over time. At 5 years, more patients on ropeginterferon achieved complete hematologic response and significant reduction in JAK2 allele burden compared to hydroxyurea.
Dosing: Subcutaneous injection, starting at 100 µg every two weeks, titrated up based on response (maximum 500 µg every two weeks). Some patients can eventually extend to monthly dosing.
Side effects: Flu-like symptoms (especially early in treatment), fatigue, injection site reactions, liver enzyme elevations, thyroid dysfunction, mood changes (depression — monitor carefully), cytopenias.
Preferred in younger patients: Because of its potential disease-modifying effects and lack of leukemogenic concerns, many MPN experts now prefer ropeginterferon as first-line cytoreduction in younger PV patients, particularly those of childbearing potential.

Peginterferon alfa-2a (Pegasys): Used off-label for PV for many years before ropeginterferon’s approval. The MPD-RC 112 trial showed comparable efficacy to hydroxyurea. Pegasys is now less commonly used for PV since the approval of Besremi, which was designed and approved specifically for this indication.

Hydroxyurea vs. ropeginterferon — the choice matters. Both are acceptable first-line cytoreduction. Hydroxyurea is cheaper, well-studied, and oral. Ropeginterferon requires injections and careful dose titration but may modify the disease biology. Discuss with your hematologist which is right for you, considering your age, symptom burden, tolerance, and treatment goals.

Pregnancy & Family Planning

PV can be managed successfully through pregnancy, but it is a higher-risk pregnancy that should be co-managed by a hematologist and a maternal-fetal medicine (high-risk obstetrics) specialist, ideally with planning before conception. PV raises the risk of blood clots, miscarriage, and other pregnancy complications, so the goal is to keep the blood thickness (hematocrit) controlled while using only treatments that are safe for the baby.

Medications to stop before pregnancy. Hydroxyurea and ruxolitinib (Jakafi) can harm a developing baby and are not used in pregnancy. If you are planning to conceive, talk to your hematologist well in advance about stopping these drugs and switching to a safe alternative. Effective contraception is recommended while taking them.

Phlebotomy remains safe and is used to keep the hematocrit in a pregnancy-appropriate range (your team will set the target, which is generally tighter than the usual <45%).
Low-dose aspirin is generally continued throughout pregnancy to lower clot and placental risk (confirm with your team).
Low-molecular-weight heparin (LMWH) — a self-injected blood thinner that does not cross the placenta — is often added, especially around delivery and for 6 weeks afterward (the postpartum period carries the highest clot risk), or earlier if you have had a prior clot or pregnancy complication.
Interferon (ropeginterferon/Besremi or peginterferon alfa-2a/Pegasys) is the cytoreductive treatment of choice if cytoreduction is needed during pregnancy, because it is not known to harm the baby. This is one reason interferon is often preferred in people of childbearing potential.

Questions to ask your doctor: If I want to have children, when should I stop hydroxyurea or ruxolitinib? Will I need interferon or blood thinners during pregnancy? Can you coordinate my care with a high-risk pregnancy specialist?

Symptom Management

PV causes a significant symptom burden beyond blood count abnormalities. Many patients experience debilitating symptoms that affect quality of life even when blood counts are well controlled.

One of the most characteristic and distressing symptoms of PV. Intense itching occurs after contact with water (bathing, showering, swimming), typically lasting 15–60 minutes.

First-line: Antihistamines (cetirizine, fexofenadine), SSRIs (paroxetine, fluoxetine — may be particularly effective), and phototherapy (narrowband UVB)
Second-line: Ruxolitinib is highly effective for PV-related pruritus
Practical tips: Cool or lukewarm water (not hot), minimize time in water, gentle patting dry (not rubbing), alkaline soaps, oatmeal baths

Fatigue is the most commonly reported symptom in PV and is often the most impactful on quality of life. It is often multifactorial:

Iron deficiency from phlebotomy can worsen fatigue, though iron replacement must be carefully considered (discuss with your hematologist — replacing iron may raise hematocrit and increase phlebotomy needs)
Disease-related cytokine burden: The inflammatory state of PV itself causes fatigue
Treatment side effects: Both hydroxyurea and interferon can cause fatigue
Management: Regular exercise, adequate sleep, energy conservation techniques. Ruxolitinib significantly improves fatigue scores in clinical trials.

Erythromelalgia: Burning pain, redness, and warmth in the hands and feet. Caused by microvascular platelet aggregation. Usually responds well to low-dose aspirin.
Headache and visual disturbances: Can be caused by hyperviscosity and microvascular compromise. Usually improve with hematocrit control and aspirin.
Dizziness, tinnitus, and concentration difficulties: Related to blood viscosity. Should improve as hematocrit comes under control.

The MPN Symptom Assessment Form Total Symptom Score (MPN-SAF TSS, or MPN-10) is a validated tool for tracking PV symptoms. It covers 10 key symptoms including fatigue, concentration difficulties, early satiety, inactivity, night sweats, itching, bone pain, abdominal discomfort, weight loss, and fever. Ask your hematologist about using this tool at each visit to monitor symptom burden over time.

Disease Transformation

PV is a chronic condition, but over years to decades, it can transform into more aggressive diseases. Understanding these risks helps with long-term monitoring and decision-making.

Approximately 10–15% of PV patients develop post-PV myelofibrosis over 15–20 years
Signs include: progressive anemia (falling hemoglobin), enlarging spleen, rising LDH, increasing bone marrow fibrosis, constitutional symptoms (weight loss, fevers, night sweats)
Post-PV MF is treated similarly to primary myelofibrosis — JAK inhibitors (ruxolitinib, fedratinib, pacritinib, momelotinib), and allogeneic stem cell transplant for eligible candidates
Regular bone marrow biopsies (every 2–3 years, or sooner if clinically indicated) help detect early fibrotic progression

Approximately 2–5% of PV patients develop AML or MDS over 15–20 years
This is sometimes called “blast phase” or leukemic transformation
Prognosis of MPN-transformed AML is generally poor compared to de novo AML
Risk factors for transformation include: older age, longer disease duration, high JAK2 allele burden, additional mutations (ASXL1, SRSF2, IDH1/2, TP53), prior exposure to alkylating agents or radioactive phosphorus (P-32)
There is no proven strategy to prevent transformation, though some experts hypothesize that achieving molecular responses with interferon may reduce this risk over time

How often should I have bone marrow biopsies to monitor for fibrotic progression?
Are there signs that my PV is progressing?
Do I have any additional mutations beyond JAK2 that affect my prognosis?
If my disease transforms, what would the treatment options be?
Would I be a candidate for stem cell transplant if transformation occurs?
Are there clinical trials studying prevention of transformation?

class="content-section" data-stage="advanced">

Clinical Trials — Finding and Enrolling

Clinical trials are important in PV because the treatment landscape is evolving, and several promising new therapies are being studied.

Trial	Agent(s)	Population	NCT Number
VERIFY (Phase 3)	Rusfertide (hepcidin mimetic)	PV patients requiring phlebotomy	NCT05210790
REVIVE (Phase 2)	Rusfertide (hepcidin mimetic)	PV patients needing frequent phlebotomy	NCT04057040
RESPONSE (pivotal)	Ruxolitinib vs. BAT	HU-resistant/intolerant PV with splenomegaly	NCT01243944
PROUD-PV / CONTINUATION-PV	Ropeginterferon vs. hydroxyurea	Newly diagnosed or early PV	NCT01949805
MPD-RC 112	Peginterferon alfa-2a vs. hydroxyurea	High-risk PV and ET	NCT01259856
CYTO-PV (completed, landmark)	Hematocrit <45% vs. 45–50%	PV (established hematocrit target)	NCT01645124

ClinicalTrials.gov (clinicaltrials.gov): Search for “polycythemia vera” and filter by status (recruiting), location, and intervention.
MPN Research Foundation: (mpnresearchfoundation.org) Maintains a clinical trial finder specific to MPNs.
Leukemia & Lymphoma Society (LLS) Clinical Trial Support Center: 1-800-955-4572. Free nurse navigators who help match you to trials.
Your MPN specialty center: Many centers run trials not widely advertised. Ask your hematologist what trials they have open.

International Access & Regulatory Landscape

PV drug approvals and availability vary by country. Some therapies approved in one region may not yet be available in another.

Drug	US FDA	EMA (Europe)	Other	Notes
Ropeginterferon alfa-2b (Besremi)	2021	2019 (approved 2 years earlier)	Health Canada 2022	EU was first to approve; broader indication in EU (any PV without symptomatic splenomegaly) vs. initial FDA indication (adults with PV). FDA label later expanded.
Ruxolitinib (Jakafi/Jakavi)	2014 (PV)	2015 (PV)	Widely available globally	For HU-resistant/intolerant PV. Available in most countries.
Hydroxyurea	Available (generic)	Available (generic)	Global availability	Remains first-line cytoreduction globally due to cost and availability.
Rusfertide	NDA under FDA Priority Review (decision expected H2 2026)	Not yet approved	Under review	Phase 3 VERIFY met its endpoints; NDA accepted with Priority Review (Mar 2026). Potential first-in-class hepcidin mimetic for PV.

ELN (European LeukemiaNet): PV management consensus widely followed internationally
NCCN (US): MPN guidelines updated regularly
BSH (British Society for Haematology): MPN management guidelines for UK practice
ESMO (Europe): Clinical practice guidelines for MPNs
NICE (UK): Technology appraisals for PV therapies
GIMEMA (Italy): Conducted the landmark CYTO-PV trial
Health Canada / CADTH: Canadian drug access pathway

EU vs. US interferon use: Historically, European hematologists have been more willing to use interferon as first-line therapy for PV, even before ropeginterferon’s formal approval. The EMA approved ropeginterferon in 2019, two years before the FDA. This means European practice patterns have greater experience with interferon-first approaches, and some US centers are now adopting similar strategies.

Failed & De-Adopted Therapies

Understanding what has not worked is important for informed decision-making.

DE-ADOPTED Radioactive phosphorus was used to treat PV from the 1950s through the 1980s. While effective at controlling blood counts, it was definitively associated with a significantly increased risk of leukemic transformation (AML/MDS). The PVSG-01 trial demonstrated this excess leukemia risk. P-32 is no longer used for PV.

DE-ADOPTED Alkylating agents like chlorambucil and pipobroman were used historically for PV cytoreduction but showed clearly increased rates of leukemic transformation. The PVSG trials and the French PV study demonstrated that these agents carry unacceptable leukemogenic risk. They are no longer recommended for PV.

ABANDONED Sequential or combination use of hydroxyurea with alkylating agents was studied historically but showed increased leukemia risk. Current guidelines recommend hydroxyurea monotherapy. If hydroxyurea fails, patients should switch to (not add) an alternative agent such as ruxolitinib or ropeginterferon.

LIMITED DEVELOPMENT Givinostat, an HDAC inhibitor, was studied in PV and showed hematologic responses in early-phase trials. However, development for PV has been limited, with the drug prioritized for other indications. It is not currently in late-stage development for PV.

Why this matters: If someone suggests one of these therapies, you now know its history. The key lesson from PV history is that alkylating agents and radioactive phosphorus cause leukemia, and hydroxyurea monotherapy appears safe. Always ask your hematologist about the evidence behind any recommended treatment.

class="content-section" data-stage="resources">

Specialty Centers

PV is best managed by hematologists experienced in myeloproliferative neoplasms (MPNs). While many community hematologists can manage straightforward PV, referral to an MPN specialty center is recommended for complex cases, hydroxyurea failure, disease transformation, or clinical trial access.

No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.

Huntsman Cancer Institute (HCI) — University of Utah

NCI-designated Comprehensive Cancer Center with hematologic malignancies and MPN expertise

Location: 2000 Circle of Hope Dr, Salt Lake City, UT 84112
Phone: 801-585-0303
Programs: Hematologic Malignancies Program with MPN expertise, clinical trials for myeloproliferative neoplasms, bone marrow transplant program for transformed disease.

University of Utah Hematology

Location: Salt Lake City, UT
Phone: 801-581-2121
Programs: General hematology with MPN management. Affiliated with Huntsman Cancer Institute for complex cases and clinical trials.

Intermountain Health

Phone: 801-442-2000
Programs: Hematology-oncology services across Utah and the Intermountain West. Manages PV patients in community settings with referral pathways to HCI for complex cases.

Mayo Clinic Arizona

Location: 5777 E Mayo Blvd, Phoenix, AZ 85054
Phone: 480-301-8000
Programs: MPN program with clinical trials, molecular diagnostics, and transplant capability for transformed disease.

University of Colorado Cancer Center

Location: Anschutz Medical Campus, Aurora, CO 80045
Phone: 720-848-0000
Programs: NCI-designated Comprehensive Cancer Center. MPN program with clinical trials.

How to choose. Huntsman Cancer Institute = NCI Comprehensive Cancer Center with MPN expertise, clinical trials, and molecular diagnostics. Intermountain Health = broad geographic coverage, community hematology with referral to academic centers for complex cases. Both are strong choices depending on insurance, location, and trial availability.

Information verified May 2026. Availability changes — confirm with each institution directly.

MD Anderson Cancer Center — MPN Program

Location: Houston, TX · Phone: 877-632-6789
One of the largest MPN programs in the world. Extensive clinical trial portfolio for PV, myelofibrosis, and ET. Pioneered many current MPN treatment approaches.

Memorial Sloan Kettering Cancer Center

Location: New York, NY · Phone: 212-639-2000
Dedicated MPN program. Active research in JAK2 biology, interferon therapy, and novel agents.

Mayo Clinic Rochester — MPN Program

Location: Rochester, MN · Phone: 507-538-3270
Large MPN referral center. Internationally recognized for MPN prognostic modeling (DIPSS, MIPSS-PV) and clinical trials.

Moffitt Cancer Center

Location: Tampa, FL · Phone: 888-663-3488
Active MPN program with clinical trials including novel JAK inhibitors and interferon studies.

Dana-Farber Cancer Institute

Location: Boston, MA · Phone: 617-632-3000
Harvard-affiliated. MPN program with clinical trials and translational research.

Icahn School of Medicine at Mount Sinai

Location: New York, NY · Phone: 212-241-6500
Tisch Cancer Institute MPN program. Long history of MPN research and clinical trials. Interferon expertise.

VA Hematology Care for PV

The VA system provides PV management through its hematology services. For complex cases or clinical trial access, the VA partners with academic MPN centers through community care arrangements.

George E. Wahlen VA Medical Center (Salt Lake City, UT): 801-582-1565. Partnership with Huntsman Cancer Institute for MPN specialty care.
VA Community Care: 1-877-881-7618 for referral to non-VA MPN specialists.

VA Cancer Care: cancer.va.gov

Princess Margaret Cancer Centre (UHN), Toronto

Location: 610 University Avenue, Toronto, ON M5G 2M9
Phone: 416-946-4501
Programs: One of Canada’s largest MPN programs. Clinical trials for PV and other MPNs. Ropeginterferon early adoption.

BC Cancer — Vancouver Centre

Location: Vancouver, BC
Phone: 604-877-6000
Programs: Provincial hematology referral center.

McGill University Health Centre, Montreal

Location: Montréal, QC
Phone: 514-934-1934
Programs: Hematology program with MPN expertise.

Canadian MPN Group: National clinical trials and research network for MPNs
Canadian Cancer Society helpline: 1-888-939-3333

International Centers of Excellence for MPNs

Guy’s and St Thomas’ Hospital, London, UK: Major UK MPN center with BSH guideline development
Universitätsklinikum RWTH Aachen, Germany: Leading MPN research and clinical trials
Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA), Italy: Conducted the landmark CYTO-PV trial
Medical University of Vienna, Austria: PROUD-PV/CONTINUATION-PV trial coordinating center for ropeginterferon
Peter MacCallum Cancer Centre, Melbourne, Australia: Major MPN referral center for Australasia

Caregiver Guidance

PV is a chronic condition, and caregiving for someone with PV differs from caregiving for acute cancers. The challenges are often more subtle but no less real.

Fatigue is real and often invisible. PV fatigue is not laziness — it is a disease-driven symptom caused by inflammation and altered blood function. Patients may look fine but feel exhausted.
Itching can be debilitating. Aquagenic pruritus can make simple activities like showering or swimming miserable. Support practical adaptations (cool showers, gentle drying).
Anxiety about blood clots: The constant awareness of thrombotic risk can create chronic anxiety. Acknowledge this without dismissing it.
Treatment is ongoing, not finite. Unlike many cancers that have a defined treatment period, PV treatment is lifelong. This marathon nature requires sustained support.

Call 911 or go to the emergency department immediately if the patient develops:

Sudden severe headache, confusion, or difficulty speaking (stroke)
Chest pain, shortness of breath, or irregular heartbeat (heart attack, PE)
Sudden swelling, pain, or redness in one leg (DVT)
Severe abdominal pain (splanchnic vein thrombosis)
Vision changes (retinal vein thrombosis)

MPN Research Foundation: mpnresearchfoundation.org
Leukemia & Lymphoma Society: 1-800-955-4572 (peer support, financial assistance)
MPN Advocacy & Education International: mpnadvocacy.com
Voices of MPN: voicesofmpn.com (patient stories and education)
Cancer Care: cancercare.org (free counseling and support groups)

Glossary

Allele burden: The percentage of JAK2 genes carrying the V617F mutation (variant allele frequency, VAF). Higher values indicate a larger mutant clone.
Aquagenic pruritus: Intense itching triggered by contact with water, characteristic of PV.
Budd-Chiari syndrome: Blood clot in the hepatic veins (draining the liver). An unusual site thrombosis associated with MPNs.
Cytoreductive therapy: Medication that reduces blood cell production (e.g., hydroxyurea, ropeginterferon, ruxolitinib).
ECLAP: European Collaboration on Low-Dose Aspirin in Polycythemia Vera — the trial that established aspirin as standard care.
ELN: European LeukemiaNet — publishes consensus guidelines for PV and other blood cancers.
Erythromelalgia: Burning pain, redness, and warmth in the hands and feet caused by microvascular platelet clumping. Usually responds to aspirin.
Hematocrit: The percentage of blood volume occupied by red blood cells. Target in PV is below 45%.
Hepcidin: A hormone that regulates iron absorption. Rusfertide mimics hepcidin to reduce iron available for red blood cell production.
Hydroxyurea: The most commonly used cytoreductive drug for PV. Oral medication that reduces production of all blood cell types.
JAK2 V617F: The mutation found in >95% of PV patients. Causes the JAK-STAT pathway to be permanently activated, driving excess blood cell production.
MPN: Myeloproliferative neoplasm. A group of chronic blood cancers including PV, essential thrombocythemia (ET), and myelofibrosis (MF).
Myelofibrosis: A condition where bone marrow becomes scarred (fibrotic). PV can transform into myelofibrosis over time (post-PV MF).
Phlebotomy: Therapeutic blood removal to reduce red blood cell count and hematocrit.
Post-PV MF: Myelofibrosis that develops as a transformation from polycythemia vera.
Ropeginterferon alfa-2b (Besremi): A long-acting interferon approved specifically for PV. Can reduce JAK2 allele burden.
Ruxolitinib (Jakafi): A JAK1/JAK2 inhibitor approved for PV patients resistant to or intolerant of hydroxyurea.
Rusfertide: An investigational hepcidin mimetic being studied to reduce phlebotomy requirements in PV.
Splenomegaly: Enlargement of the spleen. Common in PV due to extramedullary hematopoiesis (blood production outside the bone marrow).
Thrombosis: Formation of a blood clot inside a blood vessel. The primary complication and cause of illness in PV.

Sources and Further Reading

This guide draws on published medical literature, clinical trial records, and the work of physicians treating PV across multiple countries. Key sources are listed below.

Primary Resources

PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
ClinicalTrials.gov (clinicaltrials.gov) — Authoritative registry of clinical trials
NCCN Guidelines for Clinicians — MPNs (nccn.org) — Treatment algorithms followed by oncologists
MPN Research Foundation (mpnresearchfoundation.org) — Patient education, research funding, clinical trial support
Leukemia & Lymphoma Society (LLS) (lls.org) — Patient education, financial assistance, clinical trial support (1-800-955-4572)

Key Guideline and Trial References

CYTO-PV: Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33. (NCT01645124)
ECLAP: Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–124.
RESPONSE: Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–435. (NCT01243944)
PROUD-PV/CONTINUATION-PV: Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythemia vera (PROUD-PV and CONTINUATION-PV). Lancet Haematol. 2020;7(3):e196–e208. (NCT01949805)
NCCN MPN Guidelines v1.2026: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology — Myeloproliferative Neoplasms.
ELN PV Consensus: Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057–1069.

External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site’s privacy policy when you leave this site.

What This Guide Does Not Know

An honest guide names its own limits:

This guide cannot diagnose, risk-stratify, or treat anyone. It does not know your JAK2 allele burden, blood counts, comorbidities, thrombosis history, or personal preferences. Only your medical team can build an actual plan.
PV management is evolving. New therapies like rusfertide may change the treatment landscape. Every time-sensitive fact should be re-verified with your team and primary sources.
Drug approvals and availability vary by country. This guide focuses primarily on FDA-approved therapies. Access differs in Europe, Canada, and other regions.
Individual outcomes vary widely. Some patients live decades with minimal treatment. Others develop complications early. Risk factors describe populations, not individuals.
PV is rare enough that many doctors see few cases. If your primary care doctor or general oncologist is not experienced with MPNs, a second opinion from an MPN specialty center is the single highest-value step you can take.

A final word. PV is a chronic blood cancer, but it is one of the most manageable cancers in medicine. Most patients with PV live long, productive lives. The key is consistent monitoring, hematocrit control below 45%, aspirin, and cytoreductive therapy when needed. Get to a hematologist who knows MPNs. Track your blood counts. Take your aspirin. Attend your phlebotomy appointments. You have time. Use it wisely.